(RTTNews) - Nyxoah S.A. (NYXH) has announced the commercial launch of its Genio system in the Middle East, with the first successful implant performed at Saudi German Hospital in Dubai, UAE. Genio is ...

Nyxoah NYXH recently announced that the CY2026 Hospital Outpatient Prospective Payment System (“HOPPS”) and Ambulatory Surgery Center (“ASC”) Rule has been finalized by the U.S. Centers for Medicare & ...

Nyxoah receives FDA approval for full-body 1.5T and 3T MRI compatibility for the Genio® system to treat Obstructive Sleep Apnea (OSA) Mont-Saint-Guibert, Belgium – 9 th February 2021 – Nyxoah SA ...

Nyxoah NYXH has begun its U.S. commercial rollout of the Genio system, following FDA approval for its leadless, battery-free neurostimulation therapy for obstructive sleep apnea (OSA). The first ...

Mont-Saint-Guibert, Belgium – March 26, 2025, 8:00am CET / 3:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), that develops breakthrough treatment alternatives for ...

Assignment to New Technology APC 1580 is positive news for Nyxoah’s U.S. commercial rollout by strengthening hospital and ASC economics Mont-Saint-Guibert, Belgium – November 26, 2025, 7:45 am CET / 1 ...

Nyxoah ( ($NYXH) ) has issued an update. On December 17, 2025, Nyxoah announced the commercial launch of its Genio hypoglossal neurostimulation ...

Mont-Saint-Guibert, Belgium – August 8, 2025, 10:10pm CET / 4:10pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough ...

Nyxoah Announces Commercial Launch of Genio® Breakthrough Therapy in the Netherlands First Genio implants successfully performed at OLVG West and Zuyderland hospitals ...